TThe global Alzheimer's disease diagnostics market size was estimated at USD 9.22 billion in 2025 and is expected to reach USD 21.54 billion by 2033, projected to grow at a CAGR of 11.23% from 2026 to 2033. Increasing prevalence of Alzheimer’s Disease (AD), growing use of biomarkers in disease diagnostics, growing adoption of personalized products, and increasing technological advancements in medical imaging are some of the factors expected to drive the demand for Alzheimer’s diagnostics.
Increasing government investments and R&D studies is further propelling growth. The rising prevalence of Alzheimer's disease is a key driver of market growth. As the global population ages, the demand for early and accurate diagnostic tools continues to increase. According to the 2024 Alzheimer's Association, dementia risk rises with age, and the number of Americans with Alzheimer's is expected to grow significantly. By 2050, the population aged 65 and older is projected to reach 82 million, up from 58 million in 2022. By 2030, all baby boomers (born between 1946 and 1964) will be 65 or older, the age group most susceptible to Alzheimer's dementia.
In recent years, there has been significant progress in developing novel therapeutic drugs targeting the root causes of Alzheimer’s disease. In January 2023, the U.S. FDA granted accelerated approval to lecanemab, a treatment co-developed by Eisai Co., Ltd. and Biogen Inc. Eisai also applied for manufacturing and marketing approval in Japan, where the drug received priority review from the Ministry of Health, Labour and Welfare (MHLW). However, effective use and distribution of these drugs require technology to detect amyloid-beta (Aβ) accumulation in the brain. Conventional testing methods, such as cerebrospinal fluid (CSF) testing and amyloid PET scans, are costly and invasive, increasing the demand for simpler, less invasive diagnostic approaches.
The growing global burden of Alzheimer’s has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers in disease diagnostics. Biomarkers, particularly those detecting amyloid-beta and tau proteins in CSF through positron emission tomography (PET) imaging, play a crucial role in Alzheimer’s diagnosis. In addition, companies are launching innovative biomarker tests to support ongoing clinical trials. In March 2024, Labcorp introduced the pTau217 blood biomarker test, designed to accelerate Alzheimer’s diagnosis and improve clinical trial efficiency. This test is expected to enhance the accuracy and speed of detecting Alzheimer’s, ensuring timely treatment and disease management.
The rise of personalized medicine has underscored the importance of biomarkers in patient categorization, treatment selection, and therapeutic monitoring. This trend is expected to drive the biomarkers market’s expansion. A 2023 study published in the Journal of Alzheimer's Disease emphasized the role of precision medicine in Alzheimer’s, considering genetic, environmental, and lifestyle factors in disease progression. Similarly, an October 2021 study suggested bumetanide, an FDA-approved oral diuretic, as a potential treatment for Alzheimer’s. Research funded by the National Institute on Aging (NIA) analyzed brain tissue samples and FDA-approved drugs to explore repurposing opportunities, highlighting precision medicine’s potential in Alzheimer’s treatment.
Advancements in image analysis and machine learning algorithms have enhanced the accuracy and reliability of Alzheimer’s diagnostics through neuroimaging techniques. Diagnostic approaches have evolved from traditional cognitive assessments to advanced neuroimaging and CSF assays, allowing for early disease identification. In June 2023, Roche received FDA clearance for its CSF assay, which aids in timely diagnosis and treatment decision-making by measuring beta-amyloid and tau protein levels, two key biomarkers of Alzheimer’s pathology, in individuals aged 55 and older. These technological advancements are crucial for improving Alzheimer’s detection and management.
Ongoing research and technological innovations are driving the expansion of the Alzheimer’s diagnostics and therapeutics market. Companies continue to introduce new tests and products while engaging in strategic collaborations, mergers, and investments. A February 2024 MedPage Today article highlighted the diagnostic potential of blood biomarkers in Alzheimer’s research and clinical applications. Key industry players are advancing blood biomarker technologies to enhance global diagnostic capabilities. In August 2023, C2N Diagnostics launched the PrecivityAD2 blood test, designed to match the accuracy of PET scans and CSF tests. This test aims to assess patients with cognitive decline and Alzheimer’s symptoms, further strengthening diagnostic advancements in the field.
This product will be delivered within 1-3 business days.
Increasing government investments and R&D studies is further propelling growth. The rising prevalence of Alzheimer's disease is a key driver of market growth. As the global population ages, the demand for early and accurate diagnostic tools continues to increase. According to the 2024 Alzheimer's Association, dementia risk rises with age, and the number of Americans with Alzheimer's is expected to grow significantly. By 2050, the population aged 65 and older is projected to reach 82 million, up from 58 million in 2022. By 2030, all baby boomers (born between 1946 and 1964) will be 65 or older, the age group most susceptible to Alzheimer's dementia.
In recent years, there has been significant progress in developing novel therapeutic drugs targeting the root causes of Alzheimer’s disease. In January 2023, the U.S. FDA granted accelerated approval to lecanemab, a treatment co-developed by Eisai Co., Ltd. and Biogen Inc. Eisai also applied for manufacturing and marketing approval in Japan, where the drug received priority review from the Ministry of Health, Labour and Welfare (MHLW). However, effective use and distribution of these drugs require technology to detect amyloid-beta (Aβ) accumulation in the brain. Conventional testing methods, such as cerebrospinal fluid (CSF) testing and amyloid PET scans, are costly and invasive, increasing the demand for simpler, less invasive diagnostic approaches.
The growing global burden of Alzheimer’s has intensified the need for early detection and precise diagnosis. Advances in genomics, proteomics, and metabolomics have expanded the use of biomarkers in disease diagnostics. Biomarkers, particularly those detecting amyloid-beta and tau proteins in CSF through positron emission tomography (PET) imaging, play a crucial role in Alzheimer’s diagnosis. In addition, companies are launching innovative biomarker tests to support ongoing clinical trials. In March 2024, Labcorp introduced the pTau217 blood biomarker test, designed to accelerate Alzheimer’s diagnosis and improve clinical trial efficiency. This test is expected to enhance the accuracy and speed of detecting Alzheimer’s, ensuring timely treatment and disease management.
The rise of personalized medicine has underscored the importance of biomarkers in patient categorization, treatment selection, and therapeutic monitoring. This trend is expected to drive the biomarkers market’s expansion. A 2023 study published in the Journal of Alzheimer's Disease emphasized the role of precision medicine in Alzheimer’s, considering genetic, environmental, and lifestyle factors in disease progression. Similarly, an October 2021 study suggested bumetanide, an FDA-approved oral diuretic, as a potential treatment for Alzheimer’s. Research funded by the National Institute on Aging (NIA) analyzed brain tissue samples and FDA-approved drugs to explore repurposing opportunities, highlighting precision medicine’s potential in Alzheimer’s treatment.
Advancements in image analysis and machine learning algorithms have enhanced the accuracy and reliability of Alzheimer’s diagnostics through neuroimaging techniques. Diagnostic approaches have evolved from traditional cognitive assessments to advanced neuroimaging and CSF assays, allowing for early disease identification. In June 2023, Roche received FDA clearance for its CSF assay, which aids in timely diagnosis and treatment decision-making by measuring beta-amyloid and tau protein levels, two key biomarkers of Alzheimer’s pathology, in individuals aged 55 and older. These technological advancements are crucial for improving Alzheimer’s detection and management.
Ongoing research and technological innovations are driving the expansion of the Alzheimer’s diagnostics and therapeutics market. Companies continue to introduce new tests and products while engaging in strategic collaborations, mergers, and investments. A February 2024 MedPage Today article highlighted the diagnostic potential of blood biomarkers in Alzheimer’s research and clinical applications. Key industry players are advancing blood biomarker technologies to enhance global diagnostic capabilities. In August 2023, C2N Diagnostics launched the PrecivityAD2 blood test, designed to match the accuracy of PET scans and CSF tests. This test aims to assess patients with cognitive decline and Alzheimer’s symptoms, further strengthening diagnostic advancements in the field.
Global Alzheimer’s Disease Diagnostics Market Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. The report has segmented the global Alzheimer’s disease diagnostics market report on the basis of diagnostics technique, type, end use, and region.Diagnostics Technique Outlook (Revenue, USD Million, 2021-2033)
- Biomarkers
- Imaging Techniques
- Genetic Testing
- Cognitive Assessment Tests
Type Outlook (Revenue, USD Million, 2021-2033)
- Triage
- Diagnosis
- Screening
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Diagnostic Laboratories
- Academic and Research Institutes
- Regional Outlook (Revenue in USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Alzheimer’s Disease Diagnostics Market Variables, Trends & Scope
Chapter 4. Alzheimer’s Disease Diagnostics Market: Diagnostics Technique Estimates & Trend Analysis
Chapter 5. Alzheimer’s Disease Diagnostics Market: Type Estimates & Trend Analysis
Chapter 6. Alzheimer’s Disease Diagnostics Market: End Use Estimates & Trend Analysis
Chapter 7. Alzheimer’s Disease Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Alzheimer’s Disease Diagnostics market report include:- Quest Diagnostics
- Labcorb
- C2N diagnostics
- FujireBio
- Hoffmann-La Roche
- Quanterix
- Sysmex
- Lantheus
- Siemens Healthineers
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | December 2025 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 9.22 Billion |
| Forecasted Market Value ( USD | $ 21.54 Billion |
| Compound Annual Growth Rate | 11.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
